ABC | Volume 113, Nº3, Setembro 2019

Atualização Atualização da Diretriz de Ressuscitação Cardiopulmonar e Cuidados Cardiovasculares de Emergência da Sociedade Brasileira de Cardiologia – 2019 Arq Bras Cardiol. 2019; 113(3):449-663 355. Stiles MK, Sanders P, Disney P, Brooks A, John B, LauDH, et al. Differential effects of intravenous magnesiumon atrioventricular node conduction in supraventricular tachycardia. Am J Cardiol. 2007;100(8):1249-53. 356. Weigner MJ, Caulfield TA, Danias PG, SilvermanDI, ManningWJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615-20. 357. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, García-Dorado D,et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27(5):1079-82. 358. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol. 1996;77(11):960-6. 359. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995;75(10):693-7. 360. Kochiadakis GE, Igoumenidis NE, Simantirakis EN, Marketou ME, Parthenakis FI, Mezilis NE, et al. Intravenous propafenone versus intravenous amiodarone in themanagement of atrial fibrillation of recent onset: a placebo-controlled study. Pacing Clin Electrophysiol. 1998;21(11 Pt 2):2475-9. 361. Ellenbogen KA, Stambler BS, WoodMA, Sager PT, Wesley RC Jr, Meissner MC, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28(1):130-6. 362. AlboniP,BottoGL,BaldiN,LuziM,RussoV,GianfranchiL,etal.Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351(23):2384-91. 363. Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart. 2000;84(1):37-40. 364. Botto GL, Bonini W, Broffoni T, Molteni S, Lombardi R, Alfieri G, et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? Pacing Clin Electrophysiol. 1996;19(11 Pt 2):1939-43. 365. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GW, Perry KT. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J. 1998;136(4 Pt 1):632-42. 366. Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández- Gómez JM, Santos JM, CamachoC. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000;86(9):950-3. 367. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81(5):594-8. 368. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57(3):313-21. 369. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117(12):1518-25. 370. Reisinger J, Gatterer E, HeinzeG,Wiesinger K, Zeindlhofer E, Gattermeier M, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol. 1998;81(12):1450-4. 371. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63(13):925-9. 372. Ellenbogen KA, Dias VC, Cardello FP, Strauss WE, Simonton CA, Pollak SJ, et al. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol. 1995;75(1):45-9. 373. Fromm C, Suau SJ, Cohen V, Likouzeros A, Jellinek-Cohen S, Rose J, et al. Diltiazem vs metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department. J Emerg Med. 2015;49(2):175-82. 374. Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre- excitation syndrome. Analysis during atrial fibrillation. Circulation. 1977;56(2):260-7. 375. Akhtar M, ShenasaM, Jazayeri M, Caceres J, Tchou PJ.WideQRS complex tachycardia. Reappraisal of a common clinical problem. Ann InternMed. 1988;109(11):905-12. 376. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A newapproach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83(5):1649-59. 377. Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J. 2007;28(5):589-600. 378. Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med. 1986;104(6):766-71. 379. Wellens HJ, Conover M. The EGC in emergency decision marking.Wide QRS Tachycardia. Philadelphia: WB Saunders; 2006. p. 129-157. 380. Gupta AK, Thakur RK. Wide QRS complex tachycardias. Med Clin North Am. 2001;85(2):245-66. 381. Somberg JC, Bailin SJ, Haffajee CI, Paladino WP, Kerin NZ, Bridges D, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90(8):853-9. 382. Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, Ruskinn JN. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med. 2006;47(3):217-24. 383. Schutzenberger W, Leisch F, Kerschner K, Harringer W, Herbinger W. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J. 1989;62(5):367-71. 384. Tomlinson DR, Cherian P, Betts TR, Bashir Y. Intravenous amiodarone for thepharmacologicalterminationofhaemodynamicallytoleratedsustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment? Emerg Med J. 2008;25(1):15-8. 385. Marill KA, deSouza IS, Nishijima DK, Senecal EL, Setnik GS, Stair TO, et al. Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison. Acad Emerg Med. 2010;17(3):297-306. 386. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996;78(1):43-6. 387. Ho DS, Zecchin RP, Richards DA, Uther JB, Ross DL. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994;344(8914):18-23. 388. Taylor SE. Amiodarone: an emergencymedicine perspective. EmergMed (Fremantle). 2002;14(4):422-9. 389. Ortiz M, Martin A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38(17):1329-35. 390. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am. 2001;85(2):321-41. 635